argenx SE/€ARGX
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About argenx SE
Argenx SE is a biotechnology company primarily engaged in the development of antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary SIMPLE Antibody™ platform to create differentiated immunology solutions. One of its flagship products is efgartigimod, designed to target the neonatal Fc receptor (FcRn) to modulate antibody levels, which has gained significant attention in therapeutic areas such as neuromuscular disorders. Founded in 2008, Argenx is headquartered in Ghent, Belgium, and has expanded its operations globally. The company's strategic positioning lies in its ability to combine deep insights into disease biology with cutting-edge technology to create novel treatments. Sources:
- Argenx Official Website: www.argenx.com
- "Argenx - Company Profile and News," Bloomberg, www.bloomberg.com
Ticker
€ARGX
Sector
Primary listing
BSE
Industry
Biotechnology
Headquarters
Employees
1,599
ISIN
NL0010832176
Website
argenx SE Metrics
BasicAdvanced
€30B
35.28
€13.64
0.17
-
Price and volume
Market cap
€30B
Beta
0.17
52-week high
€658.00
52-week low
€419.80
Average daily volume
64K
Financial strength
Total debt to equity
0.71
Interest coverage (TTM)
79.79%
Profitability
EBITDA (TTM)
163.509
Gross margin (TTM)
49.59%
Net profit margin (TTM)
40.26%
Operating margin (TTM)
8.14%
Effective tax rate (TTM)
-194.04%
Revenue per employee (TTM)
€1,412,680
Management effectiveness
Valuation
Price to earnings (TTM)
35.28
Price to revenue (TTM)
12.822
Price to book
5.39
Price to tangible book (TTM)
5.57
Growth
Revenue change (TTM)
82.13%
Earnings per share change (TTM)
-382.53%
3-year revenue growth (CAGR)
90.69%
10-year revenue growth (CAGR)
81.32%
3-year earnings per share growth (CAGR)
11.40%
Bulls say / Bears say
argenx SE's lead product, VYVGART, has expanded its reach to over 10,000 patients globally across three approved indications, contributing to a 98% year-over-year growth in product net sales. (finviz.com)
The company reported strong financial results for Q4 2024, with $737 million in product net sales and a net profit of $774 million, indicating robust commercial success. (finviz.com)
argenx SE maintains a solid cash position of $3.4 billion, providing financial stability to support ongoing research and development initiatives. (finviz.com)
Despite strong sales, argenx SE reported a net income loss of $204.34 million over the trailing twelve months, indicating ongoing profitability challenges. (finance.yahoo.com)
The company's return on assets (ROA) stands at -5.51%, suggesting inefficiencies in asset utilization. (finance.yahoo.com)
argenx SE's levered free cash flow is negative at -$223.88 million, which may impact its ability to fund future operations without additional financing. (finance.yahoo.com)
Data summarised monthly by Lightyear AI. Last updated on 2 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for argenx SE stock?
argenx SE (ARGX) has a market cap of €30B as of July 15, 2025.
What is the P/E ratio for argenx SE stock?
The price to earnings (P/E) ratio for argenx SE (ARGX) stock is 35.28 as of July 15, 2025.
Does argenx SE stock pay dividends?
No, argenx SE (ARGX) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next argenx SE dividend payment date?
argenx SE (ARGX) stock does not pay dividends to its shareholders.
What is the beta indicator for argenx SE?
argenx SE (ARGX) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.